List of Ofirmev drug patents

Ofirmev is owned by Mallinckrodt Hosp.

Ofirmev contains Acetaminophen.

Ofirmev has a total of 7 drug patents out of which 0 drug patents have expired.

Ofirmev was authorised for market use on 02 November, 2010.

Ofirmev is available in solution;intravenous dosage forms.

Ofirmev can be used as modified dosing regimen for the reduction of fever; modified dosing regimen for the management of mild to moderate pain, modified dosing regimen for the management of mild to moderate pain or management of moderate to severe pain as an adjunct to opioid analgesics, modified dosing regimen for the reduction of fever; modified dosing regimen for the management of mild to moderate pain or management of moderate to severe pain as an adjunct to opioid analgesics, modified dosing regimen for the management of moderate to severe pain with adjunctive opioid analgesics.

The generics of Ofirmev are possible to be released after 11 March, 2032.

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9610265 MALLINCKRODT HOSP Reduced dose intravenous acetaminophen
Nov, 2028

(5 years from now)

US9987238 MALLINCKRODT HOSP Reduced dose intravenous acetaminophen
Nov, 2028

(5 years from now)

US10383834 MALLINCKRODT HOSP Reduced dose intravenous acetaminophen
Nov, 2028

(5 years from now)

US9610265

(Pediatric)

MALLINCKRODT HOSP Reduced dose intravenous acetaminophen
May, 2029

(6 years from now)

US9987238

(Pediatric)

MALLINCKRODT HOSP Reduced dose intravenous acetaminophen
May, 2029

(6 years from now)

US9399012 MALLINCKRODT HOSP Reduced dose intravenous acetaminophen
Sep, 2031

(8 years from now)

US9399012

(Pediatric)

MALLINCKRODT HOSP Reduced dose intravenous acetaminophen
Mar, 2032

(9 years from now)

Drugs and Companies using ACETAMINOPHEN ingredient

Market Authorisation Date: 02 November, 2010

Treatment: Modified dosing regimen for the management of moderate to severe pain with adjunctive opioid analgesics; Modified dosing regimen for the management of mild to moderate pain or management of moderate to severe pain as an adjunct to opioid analgesics; Modified dosing regimen for the reduction of fever; Modified dosing regimen for the management of mild to moderate pain

Dosage: SOLUTION;INTRAVENOUS

How can I launch a generic of OFIRMEV before it's patent expiration?
More Information on Dosage

availability in other generic markets.

Click on the highlighted region to filter.

900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight

Join them to stay ahead in capturing the next drug going generic

Other things you might be interested in